Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bill would exempt nutritional reimbursements

This article was originally published in The Tan Sheet

Executive Summary

Reps. Earl Blumenauer, D-Ore., and Ginny Brown-Waite, R-Fla., introduce July 30 the Tax Equity for Meal Replacements and Supplements Act of 2009. H.R. 3406 would exclude from employees' gross income employer-funded reimbursements of nutritional purchases with eligible health claims. In a release, Blumenauer said supplements can significantly improve health, and the measure can save money and reduce unnecessary doctor visits. The legislation follows a similar, broader bill introduced by Indiana Republican Rep. Dan Burton (1"The Tan Sheet" July 27, 2009). ... Tax advantages for infant formula: Health flexible spending arrangements could reimburse formula purchases for mothers with mastectomies who are medically unable to breastfeed, as part of H.R. 3445, introduced July 31 by Rep. Debbie Wasserman Schultz, D-Fla

You may also be interested in...



Legislation Seeks Space For Supplements On Health Care Reform Slate

Carving out a role for the dietary supplement industry in health care reform has taken on a double-edged approach. While supporting legislation focused on establishing spending on supplements as health care expenses, the industry also backs including wellness and prevention programs in health care reform plans

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103197

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel